ADEPT 7: Advancing the Development of Pediatric Therapeutics Complex Innovative Trial Design

FDA/UMD PUBLIC WORKSHOP
1–2 September 2021 (Virtual)

Workshop Objective:

- Provide a platform for scientific exchange among the FDA, other global health authorities, patient advocates, and drug developers

- Discuss application and challenges of each topic in pediatric drug development and explore how challenges in the designs can be overcome

Day 1: September 1st 10am–1:15pm

Opening remarks:

10:00–10:10 am: Welcome/Introduction (John Alexander, MD, FDA)

10:10–10:25 am: Setting the stage (Lynne Yao, FDA)

Session 1: Bridging biomarkers in Pediatric Extrapolation
Co-chairs: Lily Mulugeta (FDA) /Christine Garnett (FDA)

10:25–10:55 am: Regulatory perspective
- 10:25–10:40: FDA Perspective: Pulmonary Arterial Hypertension (Christine Garnett, FDA)
- 10:40–10:55: Industry Perspective: Model based approaches to support bridging biomarkers (Laurie Conklin, Janssen)
- 10:55–11:10: Academic Perspective (Thomas Fleming, Univ. of Washington)

11:10–11:45 am: Case example (Pediatric heart failure)
11:10-11:25: Assessing disease similarity: Heart failure in adult and pediatric patients (Daphne Hsu, Albert Einstein College of Medicine)
• 11:25-11:45: Leveraging adult data to support a biomarker extrapolation: Entresto (Ron Portman, Simon Wandel, Guenther Mueller-Velten, Novartis)

11:45 am-1:05 pm: Panel discussion
Q&A: All speakers
• Panel discussion: Daphne Hsu (Albert Einstein College of Medicine), Jialu Zhang (FDA), Norm Stockbridge (FDA), Ron Portman (Novartis), Solange Corriol-Rohou (AstraZeneca), Lynne Yao (FDA), Thomas Fleming (Univ. of Washington), Sudharshan Hariharan (FDA), Robert Nelson (J&J)

1:05-1:15 pm: Christine Garnett (FDA)

Day 2: September 2nd 10am-3:00pm
Session 2: Bayesian techniques in Pediatric Studies
Co-chairs: James Travis (FDA) / John Alexander (FDA)

10:00-10:10 am: Welcome/Introduction (James Travis, FDA)

10:10-10:55 am: Regulatory perspective
• 10:10-10:25: FDA Perspective (Mark Rothmann, FDA)
• 10:25-10:40: EMA Perspective (Andrew Thomson, EMA)
• 10:40-10:55: Industry Perspective (Meg Gamalo, Pfizer)

10:55-12:00 pm: Case examples
• 10:55-11:10: Belimumab approval for pediatric systemic lupus erythematosus (Nicky Best; Anne Hammer, GSK)
• 11:10-11:35: Assessing disease similarity: multiple sclerosis in adult and pediatric patients (Paul Lee, FDA)
• 11:35-12:00: Bayesian approach to support pediatric extrapolation in multiple sclerosis (Marius Thomas and Dieter Häring, Novartis)

12:00-1:00 Break
1:00-2:50 pm: Q&A and Panel discussion
Q&A: All speakers
Panel discussion: Nikolay Nikolov (FDA), Mark Rothmann (FDA), John Lawrence (FDA), Paul Lee (FDA), Robert Nelson (J&J), Forest Williamson
2:50–3:00: Closing remarks (Lynne Yao, FDA)